Host: Amber Burg, Therapeutic Delivery Head of Neuroscience and Ophthalmology at Fortrea

Participants: 
Leone Atkinson, Executive Medical Director of Neuroscience and Ophthalmology at Fortrea
Alicia Baker, Vice President, Head of Global Regulatory Strategy at Fortrea

Description: Digital endpoints are no longer a future ambition—they’re shaping neuroscience trials today. In this episode, we explore how digital biomarkers are gaining traction, what regulators are saying, and how biotech leaders can confidently integrate these tools into their development strategies. With insights from the Neuroscience team at Fortrea, Amber Burg, Leone Atkinson, and Alicia Baker, we’ll unpack the current landscape, share real-world regulatory wins, and look ahead to what’s next, including AI and hybrid models. Whether you're just starting to explore digital endpoints or looking to push boundaries, this episode lays the groundwork for smarter, more precise neuroscience trials